Imfinzi och tremelimumab plus kemoterapi förbättrade PFS och OS vid NSCLC i stadium IV

Imfinzi and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

POSEIDON Phase III trial showed the addition of a short course of tremelimumab to Imfinzi plus chemotherapy improved patient outcomes without an increase in treatment discontinuation.

Läs hela pressmeddelandet här